Deciphera Pharmaceuticals (FRA:D05) EV-to-Revenue : 5.56 (As of Apr. 25, 2024)

View and export this data going back to 2017. Start your Free Trial

What is Deciphera Pharmaceuticals EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Deciphera Pharmaceuticals's enterprise value is €841.8 Mil. Deciphera Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was €151.5 Mil. Therefore, Deciphera Pharmaceuticals's EV-to-Revenue for today is 5.56.

The historical rank and industry rank for Deciphera Pharmaceuticals's EV-to-Revenue or its related term are showing as below:

FRA:D05' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.61 Med: 9.05 Max: 360.4
Current: 5.52

During the past 9 years, the highest EV-to-Revenue of Deciphera Pharmaceuticals was 360.40. The lowest was 1.61. And the median was 9.05.

FRA:D05's EV-to-Revenue is ranked worse than
79.22% of 1025 companies
in the Drug Manufacturers industry
Industry Median: 2.29 vs FRA:D05: 5.52

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-25), Deciphera Pharmaceuticals's stock price is €13.70. Deciphera Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €1.78. Therefore, Deciphera Pharmaceuticals's PS Ratio for today is 7.71.

Deciphera Pharmaceuticals EV-to-Revenue Historical Data

The historical data trend for Deciphera Pharmaceuticals's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Deciphera Pharmaceuticals EV-to-Revenue Chart

Deciphera Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

106.03

65.73

3.30

6.07

6.23

Deciphera Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial															6.07	6.09	5.61	4.66	6.23

Competitive Comparison of Deciphera Pharmaceuticals's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Deciphera Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Deciphera Pharmaceuticals's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Deciphera Pharmaceuticals's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Deciphera Pharmaceuticals's EV-to-Revenue falls into.

Deciphera Pharmaceuticals EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Deciphera Pharmaceuticals's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	841.798	/	151.463
	=	5.56

Deciphera Pharmaceuticals's current Enterprise Value is €841.8 Mil.
Deciphera Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €151.5 Mil.

Deciphera Pharmaceuticals (FRA:D05) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Deciphera Pharmaceuticals's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	13.70	/	1.778
	=	7.71

Deciphera Pharmaceuticals's share price for today is €13.70.
Deciphera Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.78.

Deciphera Pharmaceuticals EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Deciphera Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Deciphera Pharmaceuticals (FRA:D05) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Deciphera Pharmaceuticals Inc (FRA:D05) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

DCPH:USA

Address

200 Smith Street, Waltham, MA, USA, 02451

Website

https://www.deciphera.com

Deciphera Pharmaceuticals Inc is a biotechnology company, which develops and manufactures kinase-inhibiting drugs for the treatment of cancers and immunological diseases. It holds a diverse pipeline of drug candidates that includes three clinical-stage and two research-stage programs. Its lead drug candidate DCC-2618 is designed to inhibit the full spectrum of mutant or amplified KIT and Pdgfra kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. In addition, it is also developing two other clinical-stage drug candidates, DCC-3014 and Rebastinib. Geographically all the operations function through the region of the United States.

Deciphera Pharmaceuticals (FRA:D05) Headlines

No Headlines